On this page
Evidence dossier
The report behind the claim
The report describes attenuation of severe cardiovascular and organ disturbances. The result does not establish a safe clinical combination with sotalol or an overdose antidote.
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy.
- Design
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Participants or model
- Rats exposed to an experimental sotalol challenge
- Endpoint
- ECG, circulation, thrombosis and multiorgan injury
- Finding on record
- The report describes attenuation of severe cardiovascular and organ disturbances.
- Limits of inference
- The result does not establish a safe clinical combination with sotalol or an overdose antidote.
The experiment in view
The study used rats exposed to an experimental sotalol challenge. Its principal measures were eCG, circulation, thrombosis and multiorgan injury. The report describes attenuation of severe cardiovascular and organ disturbances.
Reading the result closely
A medication used to create a toxic experimental state cannot be treated as an ordinary co-prescription in the summary. Altered ECG and circulation are biologically consequential, so this paper is a reason to ask about interactions, not a basis to declare them absent.
The boundary of the finding
The result does not establish a safe clinical combination with sotalol or an overdose antidote.
Related evidence, kept separate
BPC-157 after isoprenaline-induced heart injury examines cardiac electrical, biochemical, imaging and organ-injury findings. Here, the measured endpoint was eCG, circulation, thrombosis and multiorgan injury. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the What changes when a BPC-157 paper becomes a sales claim? appraisal.
On the record
The documents supporting this report.